Rubraca is intended for advanced ovarian cancer patients with a BRCA gene mutation who have already been treated with two or more chemotherapies.
The FDA also approved on Monday a diagnostic test to identify the presence of BRCA gene mutations, which was designed to be used in tandem with Rubraca, according to the report.
The FDA’s Accelerated Approval Program allows for the earlier approval of drugs to fill an unmet clinical need, according to the agency’s website. The continued approval of Rubraca is contingent on the results of two clinical trials Clovis Oncology must conduct to confirm the drug’s efficacy.
More articles on supply chain:
Amazon looking to develop ‘Uber’ for truck shipments
5 supply chain strategies to control hospital drug spending
FDA removes mental health warning from Pfizer’s anti-smoking drug
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.